Global Ganja Report

Albania is pledging another one of its endless and fruitless cannabis eradication campaigns, which never succeed in bumping the country from its spot as Europe's biggest illicit producer. The US is pressing the small Balkan nation for the campaign—and kicking in military aid.

There is a growing consensus among hemp advocates that the 0.3% limit for THC content is arbitrary and is holding back the industry. And the man widely credited with arriving at this limit himself agrees.

The Contested Border
"It seems like it is pretty much pulled out of air. We ought to be looking to science to determine an appropriate threshold, determine the level at which cannabis is psychoactive and make that the standard."

This typical view is offered by attorney Patrick Goggin of Hoban Law Group, the international firm specializing in cannabis. Goggin is one of the industry's legal heavy-hitters, and has particular experience in the question of the contested border between hemp and marijuana.

California's ArcView Market Research and its affiliated BDS Analytics have released a "2019 Update" to the 6th edition of their report on The State of Legal Marijuana Markets, which was published back in June. The Update takes stock of events in the second half of the year, and anticipates that worldwide spending on legal cannabis will grow 39.1% to $17 billion in 2019.

A contraband cannabis economy booms in the Balkan Peninsula, where the wars of the 1990s spurred an underground dope-for-guns network that still thrives today. But amid EU pressure to crack down, a legal industry is now starting to emerge.

Two bills to legalize "recreational" cannabis have been introduced in Portugal—a country that already has a thriving medical marijuana industry, and a "depenalization" policy for personal possession that has been hailed as a success by reform advocates across the world.

2018 saw historic strides toward the liberation of the cannabis plant, from the proverbial four corners of the Earth—North America to the Antipodes. Canadian legalization garnered big headlines, but there were significant breaks with the global prohibition regime in several other countries—including some seemingly unlikely candidates, in regions where the anti-cannabis stigma is deeply entrenched.

When the United Kingdom announced the historic step of rescheduling cannabis and allowing physicians to prescribe it two months ago, there was concern from patients and advocates as to whether actual herbaceous flower would be allowed, or only extracts. Now the first patient is approved to receive cannabis under the program, and it is indeed to be dried flower. The bad news: with the National Health Service barred by bureaucratic hurdles from providing it, patients are at the mercy of the market—and the price is prohibitive. 

The British government has finally capitulated to pressure from patients, activists and even regional authorities, and officially pledged to make medical cannabis products available on prescription this year. But it remains to be seen which products will win approval—and actual herbaceous cannabis is unlikely to make the cut.